-
Je něco špatně v tomto záznamu ?
High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study
T. Blažek, M. Petráš, P. Hurník, P. Matoušek, L. Knybel, ZZ. Čermáková, J. Štembírek, J. Cvek, R. Soumarová
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: In the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment. METHODS: To evaluate the prognostic potential of immune biomarkers, we conducted a prospective monocentric cohort study with loco-regionally advanced HNSCC patients indicated for definitive radiotherapy/radiochemotherapy at the Department of Oncology, Ostrava University Hospital, Czech Republic, between June 2020 and August 2023. We focused on the expression of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) relative to overall survival (OS) and specific survival rates. Associations between biomarkers and survival rates were assessed by crude and adjusted hazard ratios (cHR, aHR, respectively) obtained from Cox proportional hazards regression. RESULTS: Among a total of 55 patients within a median follow-up of 19.7 months, there were 21 (38.2%) all-cause deaths and 15 (27.3%) cancer-related deaths. An overall survival (OS) rate of 61.8% and a disease-specific survival (DSS) rate of 72.7% were recorded. A significant association between survival rates and a ≥10% difference in PD-L1 expression on immune versus tumor cells (high PD-L1IC expression) was documented regardless of the type of analysis (univariate or multivariate). In addition, a stronger association was confirmed for OS and the composite biomarker high PD-L1IC expression along with either median-higher CD8+ TIL count or increased TIL density ≥30%, as indicated by an aHR of 0.08 (95% CI, 0.01 to 0.52) and 0.07 (95% CI, 0.01 to 0.46), respectively. Similar results were demonstrated for other specific survival rates. DISCUSSION: The early outcomes of the present study suggest the utility of a strong prognostic factor involving a composite biomarker high PD-L1IC expression along with increased TIL density in HNSCC patients undergoing definitive radiotherapy and radiochemotherapy. TRIAL REGISTRATION: The study is registered with Clinicaltrials.gov. - NCT05941676.
3rd Faculty of Medicine Charles University Prague Czechia
Department of Oncology Královské Vinohrady University Hospital Prague Czechia
Department of Oncology Ostrava University Hospital Ostrava Czechia
Department of Orofacial Surgery Ostrava University Hospital Ostrava Czechia
Department of Otorhinolaryngology Ostrava University Hospital Ostrava Czechia
Department of Pathology Ostrava University Hospital Ostrava Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013062
- 003
- CZ-PrNML
- 005
- 20250422074824.0
- 007
- ta
- 008
- 240723e20240404sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fonc.2024.1346793 $2 doi
- 035 __
- $a (PubMed)38638854
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Blažek, Tomáš $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 245 10
- $a High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study / $c T. Blažek, M. Petráš, P. Hurník, P. Matoušek, L. Knybel, ZZ. Čermáková, J. Štembírek, J. Cvek, R. Soumarová
- 520 9_
- $a INTRODUCTION: In the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment. METHODS: To evaluate the prognostic potential of immune biomarkers, we conducted a prospective monocentric cohort study with loco-regionally advanced HNSCC patients indicated for definitive radiotherapy/radiochemotherapy at the Department of Oncology, Ostrava University Hospital, Czech Republic, between June 2020 and August 2023. We focused on the expression of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) relative to overall survival (OS) and specific survival rates. Associations between biomarkers and survival rates were assessed by crude and adjusted hazard ratios (cHR, aHR, respectively) obtained from Cox proportional hazards regression. RESULTS: Among a total of 55 patients within a median follow-up of 19.7 months, there were 21 (38.2%) all-cause deaths and 15 (27.3%) cancer-related deaths. An overall survival (OS) rate of 61.8% and a disease-specific survival (DSS) rate of 72.7% were recorded. A significant association between survival rates and a ≥10% difference in PD-L1 expression on immune versus tumor cells (high PD-L1IC expression) was documented regardless of the type of analysis (univariate or multivariate). In addition, a stronger association was confirmed for OS and the composite biomarker high PD-L1IC expression along with either median-higher CD8+ TIL count or increased TIL density ≥30%, as indicated by an aHR of 0.08 (95% CI, 0.01 to 0.52) and 0.07 (95% CI, 0.01 to 0.46), respectively. Similar results were demonstrated for other specific survival rates. DISCUSSION: The early outcomes of the present study suggest the utility of a strong prognostic factor involving a composite biomarker high PD-L1IC expression along with increased TIL density in HNSCC patients undergoing definitive radiotherapy and radiochemotherapy. TRIAL REGISTRATION: The study is registered with Clinicaltrials.gov. - NCT05941676.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Petráš, Marek $u Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Hurník, Pavel $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Department of Pathology, Ostrava University Hospital, Ostrava, Czechia
- 700 1_
- $a Matoušek, Petr, $d 1973- $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Department of Otorhinolaryngology, Ostrava University Hospital, Ostrava, Czechia $7 xx0068189
- 700 1_
- $a Knybel, Lukáš $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia
- 700 1_
- $a Čermáková, Zuzana Zděblová $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia
- 700 1_
- $a Štembírek, Jan $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Department of Orofacial Surgery, Ostrava University Hospital, Ostrava, Czechia
- 700 1_
- $a Cvek, Jakub $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia
- 700 1_
- $a Soumarová, Renata $u Third Faculty of Medicine, Charles University, Prague, Czechia $u Department of Oncology, Královské Vinohrady University Hospital, Prague, Czechia
- 773 0_
- $w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 14 (20240404), s. 1346793
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38638854 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20250422074826 $b ABA008
- 999 __
- $a ok $b bmc $g 2125585 $s 1224925
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 14 $c - $d 1346793 $e 20240404 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
- LZP __
- $a Pubmed-20240723